Enhancing T-Cell Responses to Vaccination of HIV-1 infected Subjects on Antiretroviral Therapy

Simple item page
dc.contributor.advisorJean D. Boyer
dc.contributor.authorRamirez, Lorenzo Antonio
dc.date2023-05-17T12:53:21.000
dc.date.accessioned2023-05-22T16:33:07Z
dc.date.available2001-01-01T00:00:00Z
dc.date.copyright2015-11-16T00:00:00-08:00
dc.date.issued2014-01-01
dc.date.submitted2015-11-16T13:06:36-08:00
dc.description.abstractWith the advancement in anti-retroviral therapy (ART) regimens there has been a significant improvement in the quality of life and survival of those individuals infected with HIV-1. Even with the benefits to CD4+ cell counts, decrease in viremia and inflammatory biomarkers, HIV-1 infected individuals continue to exhibit functional issues in their T-cell immune responses to recall antigens and vaccines. Additionally, researchers believe that T-cell mediated responses will be important to elicit in a therapeutic vaccination setting. These T-cell functionality issues can leave individuals infected with HIV-1 at risk from opportunistic infections and co-morbidities. Furthermore, a therapeutic HIV-1 vaccine is needed that can elicit responses to help infected subjects better control HIV infection so as to potentially reduce the need for long-term therapy. However, basic research on HIV is still needed to solidify potential immune correlates against HIV and other pathogens affecting HIV-1 infected subjects. Likewise, investigation of therapeutic targets that can aid in enhancing T-cell immune responses in these individuals is of importance. In this thesis, we examined whether a therapeutic HIV-1 DNA vaccine delivered with in vivo electroporation to HIV-1 infected subjects on ART could elicit potent cellular immune responses previously suggested to be important in the control of HIV. This vaccine strategy demonstrated an enhancement in cell-mediated IFN-γ production and cytotoxic immune responses to HIV-1. However, until a vaccine or therapy for HIV-1 is developed, these individuals also continue to be at risk for other opportunistic infections, such as influenza infection. Supported by previous studies that focus on influenza vaccination, we found that a standard dose of the H1N1 vaccine (15μg; Novartis) did not elicit sero-protection in all individuals. Importantly, the ability of these individuals to respond to vaccination was associated with the frequency of naïve CD4+ T-cells prior to vaccination, thereby reinforcing the importance of CD4+ T-cell help and the need for better CD4+ T-cell reconstitution. In addition, HIV-1 infected subjects, despite ART, have an altered cytokine/chemokine environment. Thereby it is important to explore whether targeting the cytokine milieu can lead to improvements in responses to vaccination in these individuals. We specifically found that the pro-inflammatory chemokine IP-10 was elevated in the sera of those infected with HIV-1 while on ART. Additionally, elevated levels of IP-10 were associated with decreased cellular immune responses, which could be improved by neutralizing IP-10 prior to antigen stimulation. Therefore, the studies herein support the need for better understanding of the basic science of HIV-1 infection to uncover and comprehend what potential immune correlates are needed for therapeutic treatment of these individuals.
dc.description.degreeDoctor of Philosophy (PhD)
dc.format.extent175 p.
dc.format.mimetypeapplication/pdf
dc.identifier.urihttps://repository.upenn.edu/handle/20.500.14332/28222
dc.languageen
dc.legacy.articleid3225
dc.legacy.fulltexturlhttps://repository.upenn.edu/cgi/viewcontent.cgi?article=3225&context=edissertations&unstamped=1
dc.provenanceReceived from ProQuest
dc.rightsLorenzo Antonio Ramirez
dc.source.issue1413
dc.source.journalPublicly Accessible Penn Dissertations
dc.source.statuspublished
dc.subject.otherAntiretroviral Therapy
dc.subject.otherchemokine
dc.subject.otherCXCL10
dc.subject.otherHIV-1
dc.subject.otherIP-10
dc.subject.otherT-cell
dc.subject.otherAllergy and Immunology
dc.subject.otherImmunology and Infectious Disease
dc.subject.otherMedical Immunology
dc.subject.otherMedicine and Health Sciences
dc.subject.otherVirology
dc.titleEnhancing T-Cell Responses to Vaccination of HIV-1 infected Subjects on Antiretroviral Therapy
dc.typeDissertation/Thesis
digcom.contributor.authorisAuthorOfPublication|email:ramirezl@mail.med.upenn.edu|institution:University of Pennsylvania|Ramirez, Lorenzo Antonio
digcom.date.embargo2001-01-01T00:00:00-08:00
digcom.identifieredissertations/1413
digcom.identifier.contextkey7851216
digcom.identifier.submissionpathedissertations/1413
digcom.typedissertation
dspace.entity.typePublication
relation.isAuthorOfPublication6c2363e4-4ae1-482c-8492-dda3bdbb1883
relation.isAuthorOfPublication.latestForDiscovery6c2363e4-4ae1-482c-8492-dda3bdbb1883
upenn.graduate.groupCell & Molecular Biology
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Ramirez_upenngdas_0175C_11369.pdf
Size:
6.23 MB
Format:
Adobe Portable Document Format
Download
Collection
Dissertations and Theses